Kiera Murphy, an associate in the San Diego office of Latham & Watkins and a member of the Healthcare & Life Sciences Practice. She advises clients on regulatory and transactional matters involving industries overseen by the Food and Drug Administration (FDA) and other federal health authorities.
Ms. Murphy represents pharmaceutical, biotechnology, medical device, digital health, and consumer product companies on FDA regulatory compliance and enforcement matters. She counsels at all stages of the product life cycle, including, among others, pre-market regulatory communications and submissions, contract matters relating to clinical trials, non-patent exclusivity, post-market actions and recalls, and administrative interactions and appeals.
Ms. Murphy provides counsel concerning legislation and administrative rulemaking, including matters involving the implementation of the, 21st Century Cures Act, and the Family Smoking Prevention and Tobacco Control Act of 2009. She has been involved in Administrative Procedure Act litigation related to FDA actions and regulatory programs.
Ms. Murphy also advises investment banks, venture capital firms, private equity firms, and commercial lenders on regulatory matters in connection with mergers and acquisitions, equity offerings, financings, and other transactions in the life sciences sector.
Her experience also includes matters involving the Drug Enforcement Administration (DEA), US Department of Agriculture (USDA), and Federal Trade Commission (FTC), and other regulatory authorities with jurisdiction over healthcare and biotechnology.
Ms. Murphy earned her J.D. from the Indiana University Maurer School of Law, and her B.S. in Biomedical Sciences from Colorado State University. She also currently serves as a member of the Food and Drug Law Institute’s California Programing Committee.